Big Pharma mobilization and a series of approval firsts dominated the seasonal cell and gene therapy review, but failures in patient access post-commercialization took the top spot. In what has become a highlight of Phacilitate’s Advanced Therapies Week, Susan Nichols, chief business officer at ViroCell Biologics, highlighted 10 events from 2022 that drove conversation, investment, and innovation in regenerative medicine. She told delegates in Miami, Florida the past 12 months saw “the highest of the highs” in the cell and…